



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Lacy

Phone: 650-351-4730

E-mail: investor@gbt.com


Stock Performance

GBT (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$48.48
Change (%)	▲ 0.57 (1.19%)
Volume	258,447
52 Week Low	\$30.15
Market Cap	\$2,660,417,243
Rolling EPS	-3.42
PE Ratio	0

Shares Outstanding 55,529,477

Data as of 01/18/19 12:39 p.m. ET



Recent Headlines & Events

01/03/19

[GBT Announces New Employment Inducement Grants](#)

01/02/19

[GBT to Present at the 37th Annual J.P. Morgan Healthcare Conference](#)

12/21/18

[GBT Appoints Dawn Svoronos to Board of Directors](#)

There are currently no events scheduled.

SEC Filings

Filing Date	Form
12/21/18	<u>4</u>
12/21/18	<u>3</u>
12/21/18	<u>8-K</u>
12/12/18	<u>8-K</u>

Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.